BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32385075)

  • 21. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
    Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
    Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
    Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
    PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression.
    Li N; Liu Q; Han Y; Pei S; Cheng B; Xu J; Miao X; Pan Q; Wang H; Guo J; Wang X; Zhang G; Lian Y; Zhang W; Zang Y; Tan M; Li Q; Wang X; Xiao Y; Hu G; Jiang J; Huang H; Qin J
    Nat Commun; 2022 Nov; 13(1):7281. PubMed ID: 36435834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
    Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
    EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
    Maxwell PJ; Neisen J; Messenger J; Waugh DJ
    Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
    Ruan H; Bao L; Tao Z; Chen K
    Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
    Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
    Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
    Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
    PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
    Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
    PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.
    Yang R; Cai TT; Wu XJ; Liu YN; He J; Zhang XS; Ma G; Li J
    Immunology; 2018 Oct; 155(2):263-272. PubMed ID: 29770434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
    Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
    Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased T-cell Infiltration Elicited by
    Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
    Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
    Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.
    Patnaik A; Swanson KD; Csizmadia E; Solanki A; Landon-Brace N; Gehring MP; Helenius K; Olson BM; Pyzer AR; Wang LC; Elemento O; Novak J; Thornley TB; Asara JM; Montaser L; Timmons JJ; Morgan TM; Wang Y; Levantini E; Clohessy JG; Kelly K; Pandolfi PP; Rosenblatt JM; Avigan DE; Ye H; Karp JM; Signoretti S; Balk SP; Cantley LC
    Cancer Discov; 2017 Jul; 7(7):750-765. PubMed ID: 28274958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.